Abstract
We report two pediatric patients with end-stage renal failure who developed heparin-induced thrombocytopenia type II (HIT II) on hemodialysis (HD). Both developed acute respiratory distress and chest pain within 30 min of initiating the 5th HD session. The platelets dropped during HD from 168 to 38×109/l and from 248 to 109×109/l, respectively. Marked clots were observed in the dialyzers. Substitution of heparin with the low molecular weight heparin dalteparin had no effect. Switching from anticoagulation to the heparinoid danaparoid resulted in immediate disappearance of all adverse effects, and further long-term HD was uneventful. HIT II was diagnosed clinically; heparin-induced platelet activation test (HIPA) and serum IgG, IgA, and IgM to heparin-platelet factor 4 complexes (HPF4) were both negative. We conclude that HIT II may occur in children on HD. HIT II is essentially a clinical diagnosis, as HIPA and antibodies to HPF4 are not always positive. Once HIT II is suspected, heparin (and low-molecular-weight heparins) should be stopped immediately. Long-term anticoagulation with danaparoid is a valuable option for patients on HD.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 22 July 1999 / Revised: 29 November 1999 / Accepted: 13 December 1999
Rights and permissions
About this article
Cite this article
Neuhaus, T., Goetschel, P., Schmugge, M. et al. Heparin-induced thrombocytopenia type II on hemodialysis: switch to danaparoid. Pediatr Nephrol 14, 713–716 (2000). https://doi.org/10.1007/PL00013423
Issue Date:
DOI: https://doi.org/10.1007/PL00013423